Source comparison
Comparison: PT-141 vs Other HSDD Interventions
Bremelanotide (PT-141) Melanocortin MC3R/MC4R receptor agonist. Central action on hypothalamic desire circuits 25% vs 17% placebo Subcutaneous injection 1.75mg as needed before activity Nausea (40%), flushing, injection site reactions FDA-approved 2019 for pre
This comparison does not assign a generated winner or score.
- Bremelanotide (PT-141)
- Melanocortin MC3R/MC4R receptor agonist. Central action on hypothalamic desire circuits
- 25% vs 17% placebo
- Subcutaneous injection 1.75mg as needed before activity
- Nausea (40%), flushing, injection site reactions
- FDA-approved 2019 for premenopausal HSDD
- Flibanserin (Addyi)
- Serotonin 5-HT1A agonist / 5-HT2A antagonist. Modulates neurotransmitter balance related to desire
- 10–15% above placebo rates
- Oral 100mg daily at bedtime
- Dizziness, somnolence, hypotension (especially with alcohol)
- FDA-approved 2015 for premenopausal HSDD
- Testosterone therapy (off-label)
- Androgenic receptor activation. Increases libido through hormonal pathways
- Variable, 30–50% report subjective improvement in small trials
- Topical gel or transdermal patch (off-label dosing)
- Virilization risk, lipid changes, not FDA-approved for this indication
- Not FDA-approved for female HSDD. Used off-label
- Cognitive-behavioral therapy
- Addresses psychological contributors to low desire. Relationship dynamics, stress, negative cognitions
- 40–60% report improvement in observational studies
- Weekly or biweekly therapy sessions over 12–16 weeks
- None (non-pharmacological)
- Not a pharmaceutical. First-line recommendation in clinical guidelines
- PT-141 studied HSDD research is the only intervention approved specifically for as-needed use rather than daily dosing, which aligns with situational desire patterns for some women. However, the 25% responder rate is lower than cognitive-behavioral therapy outcomes in head-to-head comparisons, and PT-141 doesn't address relational or psychological contributors to HSDD. It only works if the issue is neurobiological signaling rather than external stressors or unresolved relationship dynamics.